scPharmaceuticals (NASDAQ:SCPH - Get Free Report) is anticipated to release its Q2 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect scPharmaceuticals to post earnings of ($0.30) per share and revenue of $15.41 million for the quarter.
scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.04). The company had revenue of $16.04 million for the quarter, compared to the consensus estimate of $15.41 million. scPharmaceuticals had a negative return on equity of 594.07% and a negative net margin of 216.24%. On average, analysts expect scPharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
scPharmaceuticals Stock Down 7.8%
NASDAQ SCPH traded down $0.39 on Friday, reaching $4.62. The company had a trading volume of 366,887 shares, compared to its average volume of 377,096. The company has a quick ratio of 4.61, a current ratio of 5.48 and a debt-to-equity ratio of 3.86. The company's fifty day moving average is $4.44 and its 200 day moving average is $3.46. scPharmaceuticals has a 52-week low of $1.94 and a 52-week high of $6.28. The stock has a market capitalization of $243.73 million, a P/E ratio of -2.40 and a beta of 0.40.
Institutional Trading of scPharmaceuticals
Several institutional investors and hedge funds have recently made changes to their positions in the company. Rhumbline Advisers grew its position in scPharmaceuticals by 21.0% in the 1st quarter. Rhumbline Advisers now owns 51,499 shares of the company's stock worth $135,000 after purchasing an additional 8,945 shares in the last quarter. Comerica Bank boosted its stake in shares of scPharmaceuticals by 22.1% in the 1st quarter. Comerica Bank now owns 38,662 shares of the company's stock worth $102,000 after buying an additional 7,000 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of scPharmaceuticals in the 1st quarter worth approximately $76,000. Hedge funds and other institutional investors own 89.52% of the company's stock.
About scPharmaceuticals
(
Get Free Report)
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.
Featured Stories
Before you consider scPharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and scPharmaceuticals wasn't on the list.
While scPharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access